On Pfizer's heels, GSK boasts 'truly exceptional' PhIII data for RSV vaccine — making a beeline to FDA
Pfizer won’t be the only drugmaker to file an RSV vaccine with the FDA this year.
GSK — another frontrunner in the long race to develop a shot that can protect the elderly from respiratory syncytial virus infections — is out with what CSO Tony Wood calls “truly exceptional” Phase III results, opening the door to regulatory submissions in 2022.
The update marks a key and much-needed win for GSK’s RSV ambitions after an observation related to safety forced it to stop trials in pregnant women. It had hoped that by vaccinating pregnant women, it could immunize babies against the virus.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters